Kymera Therapeutics
Yahoo Finance • 2 days ago
Kymera Therapeutics Gets FDA Fast Track Status For KT-621 In Asthma
(RTTNews) - Kymera Therapeutics, Inc. (KYMR) on Monday said the U.S. Food and Drug Administration has granted Fast Track designation to its investigational drug KT-621 for the treatment of moderate to severe eosinophilic asthma. KT-621 is... Full story
Yahoo Finance • 14 days ago
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story
Yahoo Finance • 18 days ago
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expect... Full story
Yahoo Finance • last month
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
On February 17, 2026, Boxer Capital Management, LLC disclosed a buy of 135,000 shares of Celcuity(NASDAQ:CELC), an estimated $11.10 million trade based on quarterly average pricing. What Happened According to a February 17, 2026, SEC fil... Full story
Yahoo Finance • last month
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing
On February 17, 2026, Boxer Capital Management, LLC disclosed a new position in Terns Pharmaceuticals(NASDAQ:TERN), acquiring 375,000 shares in a transaction estimated at $15.15 million based on quarterly average pricing. What Happened B... Full story
Yahoo Finance • 2 months ago
Kymera (KYMR) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Feb. 26, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Nello MainolfiChief Medical Officer — Jared GollobChief Financial Officer — Bruce Jacobs Need a quote from a Motle... Full story
Yahoo Finance • 4 months ago
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story
Yahoo Finance • 4 months ago
Kymera Therapeutics Reaches Analyst Target Price
In recent trading, shares of Kymera Therapeutics Inc (Symbol: KYMR) have crossed above the average analyst 12-month target price of $38.69, changing hands for $40.49/share. When a stock reaches the target an analyst has set, the analyst l... Full story
Yahoo Finance • 4 months ago
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story
Yahoo Finance • 4 months ago
Kymera jumps on early-stage data for eczema candidate KT-621
[a girl scratches the skin on the elbow of her arm, redness is atopic dermatitis, the girl s face is not visible] Evgeniia Gordeeva * Kymera Therapeutics (KYMR [https://seekingalpha.com/symbol/KYMR]) is up ~51% in Monday trading after r... Full story
Yahoo Finance • 4 months ago
Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema. Continue Reading... Full story
Yahoo Finance • 4 months ago
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatit... Full story
Yahoo Finance • 4 months ago
Healthcare Names Post Strong After-Hours Moves: KYMR, OCUL, POAI Among Top Gainers
(RTTNews) - Several healthcare and biotech names posted notable gains in Friday's after-hours trading session, with momentum driven by clinical updates, recent announcements, and technical rebounds. Kymera Therapeutics Inc. (KYMR) surged... Full story
Yahoo Finance • 4 months ago
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advan... Full story
Yahoo Finance • 5 months ago
Here Are Wednesday’s Top Wall Street Analyst Research Calls: DHL Group, NetApp, Nutanix, Oracle, Snowflake, Urban Outfitters, Zscaler and More
Bet_Noire / iStock via Getty Images Quick Read After a mixed start on Tuesday, all the major indices closed higher as hopes for a December rate cut rose. With the market holiday on Thursday and an early close for Friday, trading could re... Full story
Yahoo Finance • 5 months ago
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with data to be reporte... Full story
Yahoo Finance • 5 months ago
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story
Yahoo Finance • 5 months ago
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today an... Full story
Yahoo Finance • 6 months ago
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will rep... Full story
Yahoo Finance • 6 months ago
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies KT... Full story
